



Personalised Cancer Medicine Flashcards 2025

Ovarian Cancer



Standard

BRCA1 and BRCA2*
Homologous Recombination
Deficiency (HRD)**

*germ-line and somatic
**somatic

Recommended

NGS*
FR α (alfa-folate receptor)**
Microsatellite instability
(MSI-H, dMMR)***
HER2****

*Germinal multigene panel (including PALB2, CHECK2, RAD51C, RAD51D, BRIP1, MLH1, MSH2, MSH6, PSM2)
**by IHC
***by IHC (MLH1, MSH2, MSH6, PSM2) or genomic study (BAT25, BAT26, DS2123, D5S346, D17S250)
****by IHC (3+/2+)

Currently not recommended

PD1/PDL1, BARD1,
CHECK1, p53,
FAM175A, MRE11A,
NBN

The **Standard** category is based on current treatment indications with approved funding by the Spanish National Health System
The **Recommended** category is based on current recommendations by EMEA and FDA

1. NCCN Guidelines Version 3.2025 Breast, Ovarian, Pancreatic, and Prostate Cancer Genetic Assessment.
2. Newly diagnosed and relapsed epithelial ovarian cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. González-Martín, A. et al. Annals of Oncology, Volume 34, Issue 10, 833 - 848
3. Oaknin A, Guarch R, Barretina P, et al. Recommendations for biomarker testing in epithelial ovarian cancer: a National Consensus Statement by the Spanish Society of Pathology and the Spanish Society of Medical Oncology. Clin Transl Oncol. 2018 Mar;20(3):274-285. doi: 10.1007/s12094-017-1719-x.



Cátedra de
Medicina Personalizada de Precisión

UAM Universidad Autónoma
de Madrid

